By STEVEN ZECOLA
Recursion Prescription drugs introduced outcomes at present for one its AI-discovered remedies. I used to be happy to see the big, sustained discount in polyps attributable to its therapy for Familial Adenomatous Polyposis. Recursions’ oral medicine might be seen by the normal scientific and regulatory group as “promising”.
Then again, I used to be disenchanted to not see/hear any reference to the financial savings of the price to society from this therapy and a obscure reference to working with the FDA in 1H2026. Fairly frankly, the urgency appeared to be missing.
At the moment, treating FAP is an costly, lifelong endeavor for the 50,000+ survivors. Early detection methods price $10k+ and late detection $37k+. The price to treating metastatic colorectal most cancers (for which FAP predisposes) will be extraordinarily excessive, as much as $300,000. General, the price to society from FAP simply exceeds $1 billion per yr, or greater than $15 billion on a gift worth foundation.
This medicine shouldn’t be topic to any additional regulatory delay. There’s sufficient info now on efficacy and security to have Recursion extra ahead with a broad software of this therapy, whereas persevering with take a look at dosage ranges and stratifying the affected person inhabitants. The choice is extra pointless price and struggling.
Steve Zecola offered his internet software and internet hosting enterprise when he was identified with Parkinson’s illness twenty three years in the past. Since then, he has run a consulting observe, taught in graduate enterprise faculty, and exercised extensively